- Home
- LCTX vs SCPH Comparison
LCTX vs SCPH Comparison
Compare LCTX & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- SCPH
- Stock Information
- Founded
- LCTX 1990
- SCPH 2013
- Country
- LCTX United States
- SCPH United States
- Employees
- LCTX N/A
- SCPH N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- SCPH Health Care
- Exchange
- LCTX Nasdaq
- SCPH Nasdaq
- Market Cap
- LCTX 110.2M
- SCPH 179.6M
- IPO Year
- LCTX N/A
- SCPH 2017
- Fundamental
- Price
- LCTX $0.55
- SCPH $3.38
- Analyst Decision
- LCTX Strong Buy
- SCPH Strong Buy
- Analyst Count
- LCTX 5
- SCPH 2
- Target Price
- LCTX $4.80
- SCPH $15.00
- AVG Volume (30 Days)
- LCTX 2.9M
- SCPH 442.5K
- Earning Date
- LCTX 03-06-2025
- SCPH 11-13-2024
- Dividend Yield
- LCTX N/A
- SCPH N/A
- EPS Growth
- LCTX N/A
- SCPH N/A
- EPS
- LCTX N/A
- SCPH N/A
- Revenue
- LCTX $8,719,000.00
- SCPH $30,278,000.00
- Revenue This Year
- LCTX N/A
- SCPH $172.64
- Revenue Next Year
- LCTX $41.15
- SCPH $131.43
- P/E Ratio
- LCTX N/A
- SCPH N/A
- Revenue Growth
- LCTX N/A
- SCPH 303.87
- 52 Week Low
- LCTX $0.48
- SCPH $3.08
- 52 Week High
- LCTX $1.61
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- LCTX 47.26
- SCPH 44.62
- Support Level
- LCTX $0.51
- SCPH $3.27
- Resistance Level
- LCTX $0.60
- SCPH $3.58
- Average True Range (ATR)
- LCTX 0.04
- SCPH 0.19
- MACD
- LCTX 0.01
- SCPH 0.01
- Stochastic Oscillator
- LCTX 53.85
- SCPH 22.92
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.